| Completed | Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Can NCT03032250 | Wake Forest University Health Sciences | N/A |
| Completed | Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV No NCT02245100 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | — |
| Completed | Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell C NCT02035527 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Terminated | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection NCT01249443 | AIDS Malignancy Consortium | Phase 1 |
| Completed | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT01816984 | University of Chicago | Phase 1 / Phase 2 |
| Completed | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating NCT01847326 | University of Chicago | Phase 1 |
| Terminated | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Hea NCT01528137 | Stanford University | Phase 1 |
| Terminated | Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC NCT01283178 | Virginia Commonwealth University | Phase 1 |
| Completed | TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squam NCT01334177 | University of Washington | Phase 1 |
| Withdrawn | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck C NCT01332279 | Fox Chase Cancer Center | Phase 1 |
| Completed | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurr NCT01316757 | Fox Chase Cancer Center | Phase 2 |
| Completed | Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer NCT01254617 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who D NCT01256385 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck NCT01044433 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab NCT00939627 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squam NCT00588770 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C NCT00906360 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. NCT01469429 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00507767 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer NCT00458978 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer NCT00114283 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer NCT00098631 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00096512 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the NCT00081211 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00055913 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck NCT00033618 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Ca NCT00055770 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |